Drug Trial Radar · NCT04294667
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: May 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
321
Actual
Start
Aug 12, 2020
Primary completion
May 22, 2024
Study completion Jun 4, 2024
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Mar 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Conditions
- Systemic Lupus Erythematosus
Interventions
DZPDrug
Subjects will receive dapirolizumab pegol at prespecified time-points.
PlaceboOther
Subjects will receive placebo at prespecified time-points.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Achievement of BILAG 2004-based Composite Lupus Assessment (BICLA) Response at Week 48Time frame: Week 48
Locations
177 sites in 25 countries. Site status is shown where the registry gives one.
Sl0043 50140
Birmingham, Alabama
Sl0043 50052
Phoenix, Arizona
Sl0043 50328
Tucson, Arizona
Sl0043 50383
Beverly Hills, California
Sl0043 50257
La Jolla, California
Sl0043 50275
La Palma, California
Sl0043 50378
Loma Linda, California
Sl0043 50258
Los Angeles, California
Sl0043 50340
Orange, California
Sl0043 50331
Poway, California
Sl0043 50377
San Diego, California
Sl0043 50316
San Leandro, California
Sl0043 50339
Denver, Colorado
Sl0043 50367
New Haven, Connecticut
Sl0043 50341
Washington D.C., District of Columbia
Sl0043 50239
Brandon, Florida
Sl0043 50362
Gainesville, Florida
Sl0043 50122
Miami, Florida
Sl0043 50059
Ormond Beach, Florida
Sl0043 50324
Plantation, Florida
Sl0043 50329
Tampa, Florida
Sl0043 50283
Tampa, Florida
Sl0043 50368
Atlanta, Georgia
Sl0043 50382
Atlanta, Georgia
Sl0043 50240
Idaho Falls, Idaho
Sl0043 50310
Chicago, Illinois
Sl0043 50360
Skokie, Illinois
Sl0043 50474
Hopkinsville, Kentucky
Sl0043 50285
Lake Charles, Louisiana
Sl0043 50288
Cumberland, Maryland
Sl0043 50015
Hagerstown, Maryland
Sl0043 50219
Detroit, Michigan
Sl0043 50333
Grand Blanc, Michigan
Sl0043 50273
Las Vegas, Nevada
Sl0043 50010
Brooklyn, New York
Sl0043 50366
Canton, New York
Sl0043 50266
Great Neck, New York
Sl0043 50264
Manhasset, New York
Sl0043 50077
New York, New York
Sl0043 50334
New York, New York
Showing 40 of 177 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.